 Shares of Editas Medicine Inc. EDIT, -4.10 rallied 9.3 in premarket trading on Tuesday after the company said in a news release that it had positive results from the first two patients enrolled in a Phase 12 clinical trial assessing its experimental treatment for sickle-cell disease. Editas said the therapy was well-tolerated. 